Skip to main content
. 2021 Mar 23;60(8):1015–1027. doi: 10.1007/s40262-021-00990-7

Fig. 1.

Fig. 1

Trial design (applicable to both trials). Visits 2, 3, and 4 were in-house. PK pharmacokinetic, V visit